	TTER HEALTH® Policy/Guideline			aetna™
Name: Onychomycosis			Page:	1 of 2
Effective Date: 2/13/2025		Last Review Date: 1/2025		
Applies to:	⊠Illinois ⊠New Jersey ⊠Pennsylvania Kids	□Florida ⊠Maryland □Virginia	□Michigan ⊠Florida Kids	

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for onychomycosis under the patient's prescription drug benefit.

Description:

Jublia

Jublia topical solution, 10% is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.

Kerydin

Kerydin topical solution, 5% is an oxaborole antifungal indicated for the treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.

Applicable Drug List:

Jublia Kerydin

Policy/Guideline:

The requested drug will be covered with prior authorization when the following criteria are met:

• The requested drug is being prescribed for onychomycosis of the toenail(s) due to Trichophyton rubrum or Trichophyton mentagrophytes

AND

• The patient's diagnosis has been confirmed with a fungal diagnostic test (for example, potassium hydroxide [KOH] preparation, fungal culture, or nail biopsy)


AND

• The patient had a trial and failure, or there was a contraindication, with two formulary antifungal agents (for example, itraconazole, oral terbinafine, or ciclopirox)

Approval Duration and Quantity Restrictions:

Approval: 12 months

Quantity Level Limit: Reference Formulary for drug specific quantity level limits



References:

- 1. Jublia [package insert]. Bridgewater, NJ: Bausch Health US LLC; March 2022.
- 2. Kerydin [package insert]. Melville, NY: Fougera Pharmaceuticals Inc.; August 2018.
- 3. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. https://online.lexi.com. Accessed September 10, 2024.
- 4. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 09/10/2024).
- 5. Frazier WT, Santiago-Delgado ZM, Stupka KC. Onychomycosis: Rapid Evidence Review. American Academy of Family Physicians. 2021;104:359-368.